These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36165631)

  • 1. Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
    Yamada W; Kim S; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Louie A; Peloquin CA; Schmidt S; Drusano GL; Neely M
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069522. PubMed ID: 36165631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.
    Kim S; Yamada WM; Duncanson B; Nole J; Rogers S; Parker S; Bacci M; Mtchedlidze N; Peloquin CA; Louie A; Schmidt S; Drusano GL; Neely MN
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0069321. PubMed ID: 34339275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Moxifloxacin plus Pretomanid against
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Drusano GL; Kim S; Almoslem M; Schmidt S; D'Argenio DZ; Myrick J; Duncanson B; Nole J; Brown D; Peloquin CA; Neely M; Yamada W; Louie A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
    Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
    Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
    mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
    Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
    Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
    [No Abstract]   [Full Text] [Related]  

  • 13. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
    Tasneen R; Betoudji F; Tyagi S; Li SY; Williams K; Converse PJ; Dartois V; Yang T; Mendel CM; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):270-7. PubMed ID: 26503656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building Optimal Three-Drug Combination Chemotherapy Regimens.
    Drusano GL; Neely MN; Kim S; Yamada WM; Schmidt S; Duncanson B; Nole J; Mtchedlidze N; Peloquin CA; Louie A
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.
    Saeed DK; Shakoor S; Razzak SA; Hasan Z; Sabzwari SF; Azizullah Z; Kanji A; Nasir A; Shafiq S; Ghanchi NK; Hasan R
    BMC Microbiol; 2022 Feb; 22(1):62. PubMed ID: 35209842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Regimens Containing TBI-166, a New Drug Candidate against
    Zhang Y; Zhu H; Fu L; Wang B; Guo S; Chen X; Liu Z; Huang H; Yang T; Lu Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure.
    Saeed DK; Ashraf J; Hasan Z; Shakoor S; Kanji A; Hasan R
    Tuberculosis (Edinb); 2022 Dec; 137():102266. PubMed ID: 36195000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.